激励性计费代码对初级保健中的心力衰竭管理的影响:基于人口的研究
Shijie Zhou1, Douglas S Lee1,2, Francis Nguyen3
1Division of Cardiology, University of Toronto, Toronto, Ontario, Canada.
CJC open
|September 2, 2025
概括
安大略省对心力衰竭 (HF) 护理的Q050A激励措施,在家庭医生管理的符合条件的患者中,HF药物处方的数量略有增加. 尽管如此,改变疾病的HF药物仍未得到充分利用.
科学领域:
- 心脏病学
- 医疗服务研究
- 公共卫生政策
背景情况:
- 安大略省卫生部在2008年推出了Q050A计费代码.
- 这项按绩效支付的激励措施旨在改善家庭医生对心力衰竭的指导性治疗.
- 这项研究研究了这种激励对HF药物处方模式的影响.
研究的目的:
- 评估Q050A激励和HF药物处方变化的相关性.
- 评估在激励措施实施后使用指导性HF疗法.
主要方法:
- 在安大略省的39425名66岁以上的高风患者中进行的回顾性研究,该研究由Q050A声称的FP管理.
- 对雷宁- 血管激素系统抑制剂 (RASis),β- 阻断剂 (BBs),矿物质皮质体受体抗剂 (MRAs) 和利尿剂的处方比例的分析.
- 在申请 Q050A 代码之前和之后的3个月处方数据的比较.
主要成果:
- 在激励后,处方率有所增加:RASis (45. 2% 至 45. 8%),BBs (51. 9% 至 54. 4%),MRAs (9. 2% 至 11. 7%) 和利尿剂 (63. 2% 至 65. 7%)
- 没有服用任何HF药物的患者比例显著下降 (27.5%至24. 9%,P < 0. 001).
- 新诊断的HF患者及时进行FP随访,药物使用增加最大,尽管临床上适度较小.
结论:
- Q050A激励导致心力衰竭药物处方的增加很小.
- 尽管有激励, 疾病修饰性心力衰竭药物仍未得到充分利用.
- 可能需要进一步的策略来加强指南导向治疗的采用.
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434